Renaissance Capital logo

RayzeBio Priced, Nasdaq: RYZB

Phase 3 biotech developing radiopharmaceutical therapies for cancer.

Industry: Health Care

Latest Trade: $62.49 0.00 (0.0%)

First Day Return: +33.3%

Return from IPO: +247.2%

Industry: Health Care

We are building a vertically integrated radiopharmaceutical therapeutics company with our lead program in a Phase 3 clinical trial. We are initially focused on building a market leading somatostatin receptor type 2, or SSTR2, franchise. As multiple diagnostic and therapeutic commercial products targeting SSTR2 are available, it is a clinically validated target expressed in multiple solid tumors. Our lead drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225, or Ac225, to tumors overexpressing SSTR2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225. The U.S. Food and Drug Administration, or FDA, has approved the use of DOTATATE as the peptide binder for SSTR2 diagnostic imaging and therapeutic agents. We believe that a radiopharmaceutical therapeutic, or RPT, utilizing Ac225 has the potential to provide greater efficacy over approved beta particle radioisotope Lutetium 177, or Lu177, therapies. Alpha particles deliver up to 400 times higher energy compared to beta particles leading to double-stranded DNA breaks which are lethal to cancer cells.
more less
IPO Data
IPO File Date 08/24/2023
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 17.3
Deal Size ($mm) $311
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/14/2023
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 17.3
Deal Size ($mm) $311
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
J.P. Morgan
Jefferies
more
Company Data
Headquarters San Diego, CA, United States
Founded 2020
Employees at IPO 88
Website rayzebio.com

RayzeBio (RYZB) Performance